Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SNDX Syndax Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: SNDX
Price (delayed)
$10.96
Market cap
$943.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.85
Enterprise value
$1.13B
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab,
Highlights
The revenue has soared by 85% from the previous quarter
The gross profit has soared by 84% since the previous quarter
SNDX's equity has shrunk by 56% YoY and by 25% QoQ
The net income has contracted by 38% YoY and by 3.9% from the previous quarter
Key stats
What are the main financial stats of SNDX
Market
Valuations
Earnings
Shares outstanding
86.05M
Market cap
$943.08M
Enterprise value
$1.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.38
Price to sales (P/S)
21.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.95
Revenue
$43.72M
Gross profit
$42.01M
Operating income
-$343.92M
Net income
-$331.2M
EBIT
-$318.28M
EBITDA
-$317.31M
Free cash flow
-$286.52M
Per share
Balance sheet
Liquidity
EPS
-$3.85
EPS diluted
-$3.85
Free cash flow per share
-$3.32
Book value per share
$2.5
Revenue per share
$0.51
TBVPS
$7.44
Total assets
$640.71M
Total liabilities
$425.65M
Debt
$345.63M
Equity
$215.06M
Working capital
$454.2M
Debt to equity
1.61
Current ratio
5.8
Quick ratio
5.67
Net debt/EBITDA
-0.6
Margins
Efficiency
Dividend
EBITDA margin
-725.7%
Gross margin
96.1%
Net margin
-757.5%
Operating margin
-786.6%
Return on assets
-58.4%
Return on equity
-101.6%
Return on invested capital
-60.2%
Return on capital employed
-58.3%
Return on sales
-728%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SNDX stock price
How has the Syndax Pharmaceuticals stock price performed over time
Intraday
-2.1%
1 week
8.3%
1 month
-20.17%
1 year
-41.76%
YTD
-17.1%
QTD
-10.79%
Financial performance
How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$43.72M
Gross profit
$42.01M
Operating income
-$343.92M
Net income
-$331.2M
Gross margin
96.1%
Net margin
-757.5%
The revenue has soared by 85% from the previous quarter
The gross profit has soared by 84% since the previous quarter
The operating margin has increased by 45% since the previous quarter
SNDX's net margin is up by 44% from the previous quarter
Price vs fundamentals
How does SNDX's price correlate with its fundamentals
Growth
What is Syndax Pharmaceuticals's growth rate over time
Valuation
What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.38
P/S
21.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.95
The EPS has declined by 19% year-on-year and by 3.5% since the previous quarter
SNDX's equity has shrunk by 56% YoY and by 25% QoQ
SNDX's price to book (P/B) is 18% higher than its 5-year quarterly average of 3.7
The stock's P/S is 87% below its last 4 quarters average of 168.8
The revenue has soared by 85% from the previous quarter
Efficiency
How efficient is Syndax Pharmaceuticals business performance
The company's return on equity has shrunk by 91% YoY and by 26% QoQ
The return on sales is up by 45% since the previous quarter
The return on invested capital rose by 24% year-on-year and by 16% since the previous quarter
Syndax Pharmaceuticals's return on assets has decreased by 20% YoY
Dividends
What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SNDX.
Financial health
How did Syndax Pharmaceuticals financials performed over time
The total assets is 51% more than the total liabilities
The quick ratio has contracted by 36% YoY
SNDX's current ratio is down by 35% year-on-year
SNDX's debt is 61% more than its equity
SNDX's equity has shrunk by 56% YoY and by 25% QoQ
The debt to equity has increased by 34% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.